Documents behind the reading
Every source has a scope.
A label describes its named medicine. A trial reports results in its enrolled population. A provider page documents an advertised program. These records cannot be substituted for one another.
Provider product and mechanism claims · Checked 2026-09-27
CoreAge Rx: Tirzepatide Microdosing Therapy
Read the original document ↗Articles citing this record
Provider offer; direct public HTML supplements extraction · Checked 2026-09-27
CoreAge Rx: Shared microdose GLP-1 offer and terms
Read the original document ↗Articles citing this record
Exact approved-product labeling · Checked 2026-09-27
Zepbound prescribing information, revised August 2026
Read the original document ↗Articles citing this record
- CoreAge Rx tirzepatide microdosing review: what follows from two receptors?
- Tirzepatide microdosing care comparison: match the offer to the evidence
- Ivím tirzepatide microdosing review: broader benefits need specific evidence
- Noom tirzepatide Microdose Plus review: identify the program before reading the results
- Tirzepatide and two receptors: what does the mechanism establish?
- Tirzepatide sleep-apnea evidence: where the approved use begins and ends
- Tirzepatide, biomarkers and healthspan: which outcome was actually measured?
- Tirzepatide versus semaglutide: why the trial is not a microdosing winner list
Exact approved-product labeling · Checked 2026-09-27
Mounjaro prescribing information, revised August 2026
Read the original document ↗Articles citing this record
Current regulatory safety information · Checked 2026-09-27
FDA: Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
Read the original document ↗Articles citing this record
- CoreAge Rx tirzepatide microdosing review: what follows from two receptors?
- Tirzepatide microdosing care comparison: match the offer to the evidence
- Ivím tirzepatide microdosing review: broader benefits need specific evidence
- Noom tirzepatide Microdose Plus review: identify the program before reading the results
- Tirzepatide versus semaglutide: why the trial is not a microdosing winner list
Regulatory explanation · Checked 2026-09-27
FDA: Compounding and the FDA, Questions and Answers
Read the original document ↗Articles citing this record
- CoreAge Rx tirzepatide microdosing review: what follows from two receptors?
- Tirzepatide microdosing care comparison: match the offer to the evidence
- Ivím tirzepatide microdosing review: broader benefits need specific evidence
- Noom tirzepatide Microdose Plus review: identify the program before reading the results
Provider tirzepatide program identification and access limits · Checked 2026-09-27
Noom: Microdose GLP-1Rx Plus Program
Read the original document ↗Articles citing this record
Provider marketing, care description and offer qualifications · Checked 2026-09-27
Noom: Microdose GLP-1Rx shared offer
Read the original document ↗Articles citing this record
Provider program-specific pricing explanation · Checked 2026-09-27
Noom: How much does Noom cost in 2026, updated September 22, 2026
Read the original document ↗Articles citing this record
Provider catalog and reported-outcome qualifications · Checked 2026-09-27
Noom: Medication programs and pricing directory
Read the original document ↗Articles citing this record
Provider product, service and pricing claims · Checked 2026-09-27
Ivím Health: GLP-1 Microdosing
Read the original document ↗Articles citing this record
Provider contractual service description; not an individual legal assessment · Checked 2026-09-27
Ivím Health: Terms and Conditions, effective May 27, 2026
Read the original document ↗Articles citing this record
Regulatory explanation · Checked 2026-09-27
FDA: Understanding the Risks of Compounded Drugs
Read the original document ↗Articles citing this record
Primary randomized trials, full text · Checked 2026-09-27
Malhotra and colleagues: SURMOUNT-OSA primary trial report, NEJM 2024
Read the original document ↗Articles citing this record
Historical approval announcement · Checked 2026-09-27
FDA: First medication approval for obstructive sleep apnea, December 2024
Read the original document ↗Articles citing this record
Regulatory evidence definitions · Checked 2026-09-27
FDA Facts: Biomarkers and Surrogate Endpoints
Read the original document ↗Articles citing this record
Primary randomized trial follow-up, full text · Checked 2026-09-27
Jastreboff and colleagues: Tirzepatide for Obesity Treatment and Diabetes Prevention, 2024
Read the original document ↗Articles citing this record
Primary randomized comparative trial, full text · Checked 2026-09-27
Aronne and colleagues: SURMOUNT-5 tirzepatide versus semaglutide trial, NEJM 2025
Read the original document ↗Articles citing this record
Current exact approved-product labeling · Checked 2026-09-27